MiT family translocation renal cell carcinomas: A 15th anniversary update

• Jatin S. Gandhi ^[1] ; Faizan Malik ^[1] ; Amin, Mahul B. ^[1] ; Pedram Argan ^[2] ; Armita Bahram ^[1]
  1. [1] University of Tennessee Health Science Center

     University of Tennessee Health Science Center

     Estados Unidos

     
  2. [2] John Hopkins University, Baltimore, MD, USA
• Localización: Histology and histopathology: cellular and molecular biology, ISSN-e 1699-5848, ISSN 0213-3911, Vol. 35, Nº. 2, 2020, págs. 125-136
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Microphthalmia (MiT) family translocation renal cell carcinomas (RCCs) are a heterogeneous category of renal tumors which all express MiT transcription factors, typically from chromosomal translocation and rarely from gene amplification. This tumor family has two major subtypes [i.e., Xp11 translocation RCC and t(6;11) RCC] and several related neoplasms (i.e., TFEB amplification RCC and melanotic Xp11 translocation renal cancers). Increased understanding of the clinical, pathological, molecular and prognostic heterogeneity of these tumors, since their official recognition in 2004, provides the opportunity to identify prognostic biomarkers and to understand the reasons for tumor aggression. We will review the literature from the past 15 years and highlight the need for a greater understanding of the molecular mechanisms underpinning heterogeneous tumor behavior.